Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Netflix

The best is yet to come for these winning growth stocks.

Investing $5,000 in These 2 Stocks Could Make You a Fortune

No news was good news for the healthcare stock.

Why DexCom Stock Jumped Today

DexCom's share price is volatile and is currently trading at a 20% discount to late April highs of $425. The continuous glucose monitoring device manufacturer's stock tends to spike either up or down on earnings - although they are usually positive and ahead of analyst expectations.

DexCom: Buy The Dip - Volatility Will Dissipate As Mass Market Opens Up

For these two companies, the bull case remains intact.

2 Top Growth Stocks on Sale After Earnings

While there have been rumors of Apple﻿AAPL﻿ coming up with a CGM feature in its Apple Watch, the company hasn't confirmed it yet. That said, if Apple does come up with this feature, it will surely take a toll on companies such as Dexcom and Abbott, that sell the wearable CGM devices, especially if.

Can Dexcom Stock Rebound After The Recent 11% Drop?

Investors were not pleased with the company's latest earnings report.

Why DexCom Stock Is Dropping Today

DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth.

DexCom (DXCM) Q1 Earnings and Revenues Surpass Estimates

DexCom, Inc. (DXCM) CEO Kevin Sayer on Q1 2021 Results - Earnings Call Transcript

DexCom (DXCM) delivered earnings and revenue surprises of 6.45% and 4.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

DexCom (DXCM) Surpasses Q1 Earnings and Revenue Estimates

Shares of DexCom (NASDAQ:DXCM) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 25.00% over the past year to $0.33, which beat the estimate of $0.30.

Recap: DexCom Q1 Earnings

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports First Quarter 2021 Financial Results

Dexcom Reports First Quarter 2021 Financial Results

DexCom (DXCM) has moved higher as of late, but there could definitely be trouble on the horizon for this company

DexCom (DXCM) is in Overbought Territory: What's Next?

HealthEquity

Las Vegas Sands

MercadoLibre

StoneCo

Steer clear of toxic stocks like MELI, HQY, DXCM, STNE and LVS to safeguard your portfolio.

5 Toxic Stocks That Could Break the Bank

DexCom's (DXCM) first-quarter results are likely to reflect rising global awareness of its real-time CGM.

DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?

Adobe

FedEx

Each proved its worth during the coronavirus pandemic.

3 Unstoppable Growth Stocks You Can Hold for Decades

EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today it has ended its distribution collaboration with Zkope Healthcare and is now selling the Dexcom G6 CGM system directly throughout the Netherlands. “At Dexcom, we are committed to expanding access to CGM for people with diabetes around the world. Being direct in market represents a significant step forward in allowing us to

Dexcom Starts Direct Distribution in the Netherlands

SAN DIEGO--(BUSINESS WIRE)--Dexcom Schedules First Quarter 2021 Earnings Release and Conference Call for April 29, 2021 at 4:30 p.m. Eastern Time.

Dexcom Schedules First Quarter 2021 Earnings Release and Conference Call for April 29, 2021 at 4:30 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)---- $DXCM--Dexcom Promotes Jereme Sylvain to Chief Financial Officer

Dexcom Promotes Jereme Sylvain to Chief Financial Officer

Ceridian HCM Holding Inc.

Casella Waste Systems

Hexcel

Toxic stocks are vulnerable to external shocks and are burdened with huge debts. It's important to ensure that you safeguard your portfolio from such stocks.

Keep Your Portfolio Protected From These Toxic Stocks

Becton, Dickinson and Co.

Medtronic

Axonics ModulationTechnologies Inc

When the market is expensive and overbought like the current one is, it is very important to stay with companies that not only have solid earnings potential but also have upcoming catalysts that can help move the shares higher.

4 Medical Technology Leaders Have Upcoming Catalysts That Could Be Huge

Bilibili

Capital One

Carvana

PayPal

Snap

DoorDash

Fidelity National Information

Farfetch

Lone Pine Capital, the hedge fund founded by Steve Mandel (Trades, Portfolio) in 1997, disclosed its fourth-quarter 2020 portfolio last week.

Steve Mandel's Lone Pine Reports 4th-Quarter Portfolio

Paycom Software

R1 RCM Inc

Toxic stocks usually carry huge debt load and are vulnerable to external shocks. They should be timely discarded from one's portfolio to avoid wealth erosion.

4 Toxic Stocks That Could Ruin Your Portfolio

DexCom Inc. (NASDAQ:DXCM) said it expects 2021 revenue to increase between 15% and 20% to more than $2.2 billion as it extends its diabetes care business into two new areas of the disease, prediabetes and Type 2 diabetes.

DexCom Expects More Outstanding Results in 2021

Amazon

CrowdStrike

Innovative Industrial Properties

If the market plunges, picking up these fast-paced companies at a discount would be a wise move.

4 Growth Stocks to Buy if the Stock Market Crashes

DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth.

News for DexCom Stock (DXCM)